Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/15640
Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study
Identifiers
ISSN: 1174-5886
eISSN: 1179-6901
WOS ID: 000412499300010
Scopus EID: 2-s2.0-85025818817
PMID: 28744772
Embase PUI: L617516547
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2017-09Document type
research articleCitation
Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, et al. Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study. Drugs R&D. 2017 Sep;17(3):419-25.Abstract
Introduction Breakthrough pain (BTP) management in patients with cancer is challenging, especially in the elderly. However, no studies examining the influence of age on BTP medication have been conducted. The aim of this work was to investigate the effect of sublingual fentanyl tablets (SFTs) in terms of efficacy, safety, and quality of life in two age categories. Methods We performed age subgroup analyses (<65 and <= 65 years) from a recently completed study conducted in Spain. Pain intensity (PI), onset of pain relief, frequency and duration of BTP episodes, and adverse events (AEs) were assessed at 3, 7, 15, and 30 days. Health-status instruments used were the Short Form 12, version 2 (SF12v2) questionnaire, and the Hospital Anxiety and Depression Scale (HADS-A and HADS-D). Results Twenty-six patients were aged <65 years and 54 were aged >= 65 years. SF-12v2 scores did not enhance significantly from baseline. HADS scores and PI decreased significantly at the end of the study, particularly in younger patients (HADS-A: 19.05 vs. 14.41%; HADS-D: 21.35 vs. 18.57%; PI: 67.23 vs. 56.30%). Onset of analgesia began in 2-5 min in 63.3% of subjects aged <65 years and in 36.4% of subjects aged >65 years. Most patients experienced one to five daily episodes after 30 days, and <5% needed a treatment change. AEs were less frequently reported in older individuals (20.5 vs. 36.4%). Conclusion Age subgroup analyses suggest that SFTs are an effective and safe treatment for the management of BTP in cancer patients of all ages. SFTs may offer a well-tolerated and efficient option to control cancer BTP in the elderly.
Publisher version
https://dx.doi.org/10.1007/s40268-017-0198-4MeSH
AnxietyAged
Age Factors
Spain
Analgesics, Opioid
Humans
Depression
Middle Aged
Neoplasms
Administration, Sublingual
Breakthrough Pain
Fentanyl
Quality of Life
Prospective Studies
Psychiatric Status Rating Scales
Tablets
Cancer Pain
DeCS
Dolor IrruptivoFentanilo
Dolor en Cáncer
Comprimidos
Administración Sublingual
Escalas de Valoración Psiquiátrica
Humanos
Persona de Mediana Edad
Neoplasias
Calidad de Vida
Estudios Prospectivos
Factores de Edad
Depresión
Anciano
Ansiedad
Analgésicos Opioides
España
This item appears in following Docusalut collections
Hospital Comarcal de Inca - HCIN > Comunicación científicaÁrea de Salud de Menorca - ASME > Comunicación científica